Патогенетическая роль свободно циркулирующей митохондриальной ДНК крови в формировании артериальной гипертензии

S. A. Lepekhova; E. A. Trofimova; S. V. Kirilchik; V. V. Kireeva; Yu. K. Usoltsev; K. A. Apartsin

S. A. Lepekhova Irkutsk Scientific Center of the Siberian Branch of the Russian Academy of Sciences, Irkutsk, Russia http://orcid.org/0000-0002-7961-4421
E. A. Trofimova Hospital of the Irkutsk Scientific Center of the Siberian Branch of the Russian Academy of Sciences, Irkutsk, Russia http://orcid.org/0000-0001-6629-0168
S. V. Kirilchik Irkutsk Regional Cancer Center, Irkutsk, Russia http://orcid.org/0000-0002-9997-6294
V. V. Kireeva Irkutsk Scientific Center of the Siberian Branch of the Russian Academy of Sciences, Irkutsk, Russia; Hospital of the Irkutsk Scientific Center of the Siberian Branch of the Russian Academy of Sciences, Irkutsk, Russia http://orcid.org/0000-0003-3696-9799
Yu. K. Usoltsev Hospital of the Irkutsk Scientific Center of the Siberian Branch of the Russian Academy of Sciences, Irkutsk, Russia http://orcid.org/0000-0002-2826-5911
K. A. Apartsin Irkutsk Scientific Center of the Siberian Branch of the Russian Academy of Sciences, Irkutsk, Russia http://orcid.org/0000-0003-0577-9001

Keywords: arterial hypertension, cell-free circulating mitochondrial DNA, stage of arterial hypertension, cardiovascular risk

Abstract

Studying cell-free circulating mitochondrial DNA (mtDNA) in blood plasma induces growing interest. It is assumed that an indicator of mtDNA may appear a promising clinical biomarker for assessment of the risks in the course of diseases.
The aim of this study was evaluating the relationship between the quantitative indicator of mtDNA in the blood of patients with arterial hypertension (AH) and the stage of the disease and the cardiovascular risk.

Methods. The study included 70 patients who were divided into a group with AH (n = 51) and a control group of apparently healthy patients (n = 19). All patients signed the informed consent for examination and the processing of personal data as a part of the study. Demographic data, duration of hypertension, risk factors, heredity, physical activity, anthropometric data, results of slaboratory and instrumental examinations were recorded. Concentration of mtDNA was measured by the quantitative polymerase chain reaction. A mtDNA fragment with primers FmtMinArc 5'-CTAAATAGCCCACACGTTCCC-3' and RmtMinArc 5'-AGAGCTCCCGTGAGTGGTTA-3' was used.
Results. Studying the relationships between the quantitative indicator of mtDNA in the blood and AH showed that there were no significant differences in the indicators for the level of mtDNA regardless of the AH stage. However, we noted that the number of copies tended to increase in comparison with that in conventionally healthy patients. Analysis of the cardiovascular risk showed that the quantitative indicator of mtDNA did not depend on the stage of hypertension. At the same time, the level of mtDNA was significantly increased in very high cardiovascular risk patients with AH as compared to conventionally healthy subjects: Me (LQ; UQ), 56731.2 (42531.25; 129375.0) copies/ml vs. 35156.00 (18325.00; 54956.00) copies/ml, respectively (p = 0.015).
Conclusion. The level of mtDNA in AH patients is a potential a marker for cardiovascular risk as shown by the increase in mtDNA in very high cardiovascular risk patients. Taking into account the previously demonstrated pathogenetic role of the level of mtDNA in acute coronary syndrome, the analysis should be continued. The analysis sensitivity can be increased by inclusion of quantitative indicators for the content of nuclear DNA.

Pathogenetic role of cell-free circulating mitochondrial DNA in blood in the development of arterial hypertension

Abstract